Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen.

• Tác giả: Doaa A Gamal, Aiat Morsy, Mervat Omar
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Oncotarget , 2025
• Bộ sưu tập: NCBI
• ID: 80825

Tóm tắt

BACKGROUND: Anti-epidermal growth factor receptor therapy showed an overall median survival improvement in METHOD: In our study patients received 6 cycles of 5-FU based chemotherapy with Panitumumab and patients who had partial response, complete response or stationary disease received metronomic Capecitabine with Panitumumab every 2 weeks for one year. The primary end point was progression free survival (PFS) and the secondary end points were safety, toxicity and overall survival (OS). RESULTS: The median PFS for all patients was 18 ± 1.4 months and the median OS was 45 months. Patients with synchronous metastasis and those who received Oxaliplatin based regimen with Panitumumab were found to have longer PFS compared to those with metachronous metastasis or those who received other chemotherapy regimen with accepted toxicity profile to the maintenance therapy. CONCLUSION: Using Panitumumab with metronomic Capecitabine is considered an accepted maintenance regimen in wild type